Accent Therapeutics, Inc.

Volastra Therapeutics has a goal to exploit chromosomal instability (CIN) – the process by which cancer cells divide and are able to evade the body’s normal responses – to develop a new category of ca

Ascendis Pharma A/S has two approved products and plans to submit a third drug candidate for approval later this year from its endocrinology rare disease portfolio. It also has two clinical-stage can

Who: Johnson & Johnson / Remix Therapeutics What: The two companies signed a deal to develop small molecule drugs that modulate RNA processing using Remix’s REMaster drug discovery platform, partic

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Alliances With F-star And Xencor Featur